RecruitingNot ApplicableNCT06609148
Probiotic in Patients With Bile Acid Malabsorption/Diarrhea
Randomized, Double-Blind, Placebo-Controlled Trial of De Simone Formulation Probiotic in Patients With Bile Acid Malabsorption/Diarrhea Unassociated With Ileal Resection
Sponsor
Mayo Clinic
Enrollment
24 participants
Start Date
Jan 2, 2025
Study Type
INTERVENTIONAL
Conditions
Summary
The purpose of this study is to assess effect of the DSF probiotic on fecal bile acid levels in patients with BAM.
Eligibility
Min Age: 18 Years
Inclusion Criteria12
- Prior diagnosis of bile acid malabsorption documented in the medical history based on
- either serum C4 \>52.5ng/mL, or
- fecal 48h total BA excretion \>2337 μmol/48h, or
- primary BA \>5% 48h stool collection or \>10% in single stool sample.
- For women of childbearing potential
- A negative urine pregnancy test prior to dispensing the study product
- Agreement to comply with approved methods of contraception during the whole study: unless they meet the criteria of post-menopausal, i.e. 12 months of spontaneous amenorrhea, women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, including women whose career, lifestyle, or sexual orientation precludes intercourse with a male partner, should use one or more of the following acceptable methods of contraception that should be maintained throughout the study:
- Surgical sterilization
- Hormonal contraception (implantable, patch, oral, intra-muscular)
- Intra-uterine device
- Double barrier method (diaphragm plus condom)
- At the discretion of the investigator, total abstinence is acceptable in cases where age, career, lifestyle, or sexual orientation of the patient ensures compliance
Exclusion Criteria8
- Use of oral antibiotics and probiotics within the last 4 weeks.
- Pregnancy or lactation.
- Concomitant use of bile acid sequestrants, must stop 10 days before starting 7-day stool dairy and for the duration of the study.
- History of ileal resection.
- Diabetes mellitus (type 1)
- BMI ≥ 40 kg/m\^2
- Diagnosis of gastrointestinal diseases that are associated with inflammation such as inflammatory bowel diseases and celiac diseases or gastrointestinal infection in the prior 4 weeks
- Any condition or personal circumstance that, in the opinion of the investigator, renders the subject unlikely or unable to comply with the full study protocol or could interfere with the study assessments
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DIETARY_SUPPLEMENTDe Simone formulation probiotic
Subjects will be given De Simone formulation probiotic 900 billion CFU, 3 times per day for 21-24 days
DIETARY_SUPPLEMENTPlacebo
Subjects will be given a placebo for 21-24 days
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06609148
Related Trials
Changes in Bile Acids and Microbiota in Patients With Hepatitis D Treated With Bulvertide
NCT074298641 location
Magnesium in Gastrointestinal Disease
NCT073385651 location
Treatment of Bile Acid Diarrhoea With Atorvastatin
NCT070421651 location
The 8x5 Diet for Bile Acid Diarrhoea: A Feasibility Randomised Controlled Trial
NCT062593961 location